A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Early Breast Cancer
Interventions: DRUG: Giredestrant|DRUG: Anastrozole|DRUG: Palbociclib|PROCEDURE: Surgery
Sponsor: Hoffmann-La Roche